ROCKVILLE, MD – MacroGenics, a biopharmaceutical company, announced today that its recent financial performance has exceeded analyst expectations, despite posting a net loss of $1.18 per share. The news sent shares surging, as investors celebrated the company's remarkable ability to underperform forecasts for underperformance.

“We are thrilled with these results, which clearly demonstrate our strategic commitment to losing less money than the smart people on Wall Street thought we would,” stated CEO Scott Koenig in an investor call, his voice reportedly tinged with a relief usually reserved for narrowly avoiding a meteor strike. “It’s a testament to our team’s dedication to fiscal… well, to fiscal *something*.”

Analysts were quick to praise the biotech firm's innovative approach to financial reporting. “This isn’t just beating expectations; it’s redefining what 'beating' means,” commented financial pundit Bethany Croft. “In an era where every company is chasing growth, MacroGenics has cornered the market on 'managed decline.' It’s a bold strategy, and frankly, it’s working.”

Company spokespeople confirmed that future financial guidance would include a new metric: 'Expected Negative Synergy,' which will measure how efficiently the company can convert investor capital into slightly less debt than previously projected.